CD274 and non-small cell lung carcinoma: Indeed, the CheckMate 057 study demonstrated a strong predictive value of tumor PD-L1 expression in non-squamous NSCLC [24], while no significant association between Nivolumab benefit and PD-L1 expression has been found in patients with squamous histology in the CheckMate 017 trial [23].